Dr. Frank Engler joined Certara as a Clinical Pharmacologist in 2017. He has broad experience in preclinical and clinical drug development of biologics and small molecules that spans oncology, infectious disease, and rare diseases. He currently leads project teams which focus on the application of parsimonious quantitative approaches in the areas of pharmacokinetics (PK) and pharmacodynamics (PD) to provide insights and support decision making, enabling efficient drug development for his clients. He has a wealth of hands on experience in the areas popPK/PD, PBPK, and Exposure Response.
Prior to joining Certara, Dr. Engler served as a Clinical Pharmacologist in industry where he provided strategic and quantitative support for the development of oral oncology drugs. He obtained his PhD in Pharmaceutical Sciences from the University at Buffalo, where his project involved the preclinical development of mAbs and ADCs, including assay development, in vitro and in vivo study design, and mathematical modeling.